“Comparison of Study Designs for Primary Phase III Trials for Omalizumab Versus Dupilumab for Patients With Chronic Spontaneous Urticaria”. 2023. SKIN The Journal of Cutaneous Medicine 7 (6): s299. https://doi.org/10.25251/skin.7.supp.299.